ventilator associated pneumonia. Ventilator associated pneumonia
Conditions
Interventions
Intervention 1: Control group: receiving 1 mg meropenem TDS infused over 3 hours. Intervention 2: Intervention group: receiving 2 mg meropenem TDS infused over 3 hours. Intervention 3: Intervention gr
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Definitive or probable diagnosis of VAP based upon CPIS Patients with high probability for ARC according to ARC scoring systems. (score>7) Patients receiving meropenem Patient`s serum creatinine level less than 1.3 mg/dL Patients >18 years old
Exclusion criteria
Exclusion criteria: Patients sensitive to meropenem Infection due to gram-positive bacteria Patients diagnosed with acute kidney injury Patients non-responsive to meropenem during the first 7 days of treatment and therefore needing medication change
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ft>MIC in at least 50% of dose time interval. Timepoint: days 2,3,5 during meropenem administration. Method of measurement: measuring meropenem plasma concentration by HPLC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in clinical factors. Timepoint: daily. Method of measurement: observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Sahraei
Shahid Beheshti University of Medical Sciences
Outcome results
None listed